Specialized services expansion in Europe builds on Resonant's global Biorepository offering

欧洲专业化服务的扩展依托于Resonant公司的全球生物样本库服务

to support complex clinical programs, including cell and gene therapies

以支持复杂的临床项目，包括细胞和基因疗法

LEESBURG, Va.

弗吉尼亚州利斯堡

,

，

Sept. 3, 2026

2026年9月3日

/PRNewswire/ -- Resonant Clinical Solutions, a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycle, today announced that it has acquired France-based Creapharm Bioservices from Myonex, a global clinical trial supply and packaging company with operations in the U.S., France, and Germany.

/美通社/ -- 全球临床解决方案合作伙伴 Resonant Clinical Solutions（服务于生命科学组织在临床供应链和样本生命周期中的需求）今日宣布，已从 Myonex 手中收购总部位于法国的 Creapharm Bioservices。Myonex 是一家全球临床试验供应和包装公司，在美国、法国和德国均设有业务。

The acquisition expands Resonant's Biorepository capabilities in Europe and strengthens its ability to support increasingly complex clinical programs, including cell and gene therapy trials requiring highly specialized handling and storage..

此次收购扩大了 Resonant 在欧洲的生物样本库能力，并增强了其支持日益复杂的临床项目的能力，包括需要高度专业化处理和存储的细胞和基因治疗试验。

Based in Bailly-Romainvilliers, France, Creapharm Bioservices provides specialized biobanking and cryogenic storage for biotherapeutics, Advanced Therapy Medicinal Products (ATMPs) and biological samples, including vapor-phase nitrogen storage to -196°C, mechanical freezer and cold storage, Good Manufacturing Practice (GMP) sample storage and Good Distribution Practice (GDP) quality-control sample custody.

Creapharm Bioservices 总部位于法国巴伊-罗曼维利耶，为生物治疗产品、先进治疗医药产品（ATMPs）和生物样本提供专业化的生物银行服务和低温储存服务，包括气相液氮储存（低至 -196°C）、机械冷冻和冷藏、符合药品生产质量管理规范（GMP）的样本储存，以及符合药品流通管理规范（GDP）的质量控制样本保管。

The acquisition addresses a growing need as clinical pipelines shift toward increasingly specialized modalities. A .

随着临床研发管线日益转向高度专业化的治疗模式，此次收购顺应了不断增长的需求。

study

学习

published by IQVIA in August 2025 found that non-small-molecule assets, including advanced modalities, accounted for 46% of Phase I–III clinical trial starts in 2024, up from 38% five years earlier.

IQVIA于2025年8月发布的一项研究发现，包括先进疗法在内的非小分子药物资产在2024年I–III期临床试验启动项目中占比达46%，高于五年前的38%。

'Life sciences companies increasingly need partners with the specialized expertise, infrastructure, and global reach to support more of the clinical trial lifecycle,' said Christophe Berthoux, Chief Executive Officer, Resonant Clinical Solutions. 'Creapharm Bioservices strengthens our ability to support customers developing complex and sensitive therapies, including cell and gene therapies, while complementing our existing offerings across Biorepository, Kitting, and Equipment & Ancillary services.

“生命科学公司越来越需要拥有专业知识、基础设施和全球影响力的合作伙伴，以支持更多临床试验生命周期。”Resonant Clinical Solutions 首席执行官 Christophe Berthoux 表示。“Creapharm Bioservices 增强了我们为开发复杂且敏感疗法（包括细胞和基因疗法）的客户提供支持的能力，同时补充了我们现有的生物样本库、试剂盒以及设备与辅助服务。”

Together, these capabilities advance our strategy to support more of the clinical journey at global scale.'.

这些能力共同推动了我们战略的实施，以在全球范围内为更多临床路径提供支持。

Expanding Specialized Biorepository Capabilities

扩展专业化生物样本库能力

Creapharm Bioservices is now part of Resonant's Biorepository business, expanding its global footprint and adding specialized expertise in cryogenic storage and the handling of highly sensitive biological materials. Creapharm Bioservices adds complementary capabilities including:

Creapharm Bioservices 现已并入 Resonant 的生物样本库业务，此举扩大了其全球布局，并增添了在低温储存及高敏感性生物材料处理方面的专业能力。Creapharm Bioservices 带来的互补能力包括：

Specialized cryogenic storage, with temperatures ranging from -196°C to -20°C;

专业低温存储，温度范围为-196°C至-20°C；

Chain-of-custody from controlled room temperature to cryogenic storage;

从受控室温到低温储存的监管链；

Expertise supporting biotherapeutics and advanced therapies;

支持生物治疗药物和先进疗法的专业知识；

GMP/GDP-compliant infrastructure and quality capabilities;

符合GMP/GDP要求的基础设施与质量能力；

Handling of Class 1 and Class 2 genetically modified organisms (GMOs);

1类和2类转基因生物（GMO）的处理；

Additional European infrastructure and customer relationships; and

额外的欧洲基础设施和客户关系；以及

Technical expertise in the handling and storage of highly sensitive biological materials.

在处理和高敏感性生物材料储存方面的专业技术知识。

'Creapharm Bioservices strengthens the specialized support we can provide customers that are managing increasingly sensitive materials and complex clinical programs,' said Corey Stone, Vice President and General Manager - Biorepository, Resonant Clinical Solutions. 'We are excited to welcome the Creapharm Bioservices team and build on the strong technical knowledge and customer relationships they have established.'.

“Creapharm Bioservices 增强了我们为管理日益敏感的生物材料和复杂临床试验项目的客户所提供的专业化支持，”Resonant Clinical Solutions 生物样本库副总裁兼总经理 Corey Stone 表示。“我们很高兴欢迎 Creapharm Bioservices 团队加入，并在其已建立的深厚技术积累和客户关系基础上进一步发展。”

'Creapharm Bioservices is a natural fit for Resonant,' said Greg Lavin, Chief Executive Officer of Myonex. 'Its specialized expertise is a strong complement to Resonant's global Biorepository offering. This transaction allows Myonex to further concentrate on our core strengths and future strategy, and we look forward to seeing the Creapharm Bioservices team achieve continued success under Resonant's leadership.'.

“Creapharm Bioservices 与 Resonant 天然契合，”Myonex 首席执行官 Greg Lavin 表示。“其专业能力有力地补充了 Resonant 的全球生物样本库服务。此次交易使 Myonex 能够进一步聚焦于我们的核心优势和未来战略，我们期待 Creapharm Bioservices 团队在 Resonant 的领导下继续取得成功。”

Financial terms of the transaction were not disclosed.

交易的财务条款未予披露。

About Resonant Clinical Solutions

关于 Resonant Clinical Solutions

Resonant Clinical Solutions is a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycle. Through its Biorepository, Kitting, and Equipment & Ancillary businesses, Resonant helps customers manage complexity, reduce risk, and support critical clinical programs around the world.

Resonant Clinical Solutions 是一家全球临床解决方案合作伙伴，服务于生命科学组织在临床供应链和样本生命周期中的各个环节。通过其生物样本库、配套服务以及设备与辅助用品业务，Resonant 帮助客户管理复杂性、降低风险，并支持全球范围内的关键临床项目。

With more than 850 employees across the U.S., U.K., and Europe, Resonant has supported more than 2,500 clinical trials, facilitated more than 20,000 customer-site shipments, and manages more than 100 million research assets in storage. The company serves pharmaceutical and biotechnology companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and diagnostic and reference laboratories..

Resonant 在美国、英国和欧洲拥有超过 850 名员工，已支持超过 2,500 项临床试验，完成超过 20,000 次客户现场配送，并管理着超过 1 亿件在储研究资产。该公司服务于制药和生物技术公司、合同研究组织（CRO）、合同开发与生产组织（CDMO）以及诊断和参考实验室。

Resonant's mission is to empower its partners with comprehensive, global clinical supply chain and sample lifecycle solutions that remove complexity and enable them to focus on science and patients. For more information, visit

Resonant 的使命是通过提供全面的全球临床试验供应链和样本生命周期解决方案，为合作伙伴赋能，消除复杂性，使其能够专注于科学研究和患者服务。欲了解更多信息，请访问

resonantclinical.com

resonantclinical.com

.

。

SOURCE Resonant Clinical Solutions

来源：Resonant Clinical Solutions

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示